Non-Hodgkin's Lymphoma

Pilot Trial Combines Chemotherapy/Rituximab for HIV Associated Disease

Published in AIDS Weekly, September 11th, 2000

Researchers in Italy and the United States tested cyclophosphamide, doxorubicin, and etoposide (CDE) combined with the anti-CD20 monoclonal antibody (MAb) rituximab in patients with HIV associated non-Hodgkin's lymphoma (NHL) in a pilot trial.

"The objective of this trial was to determine the feasibility of combining infusional CDE with rituximab," stated Umberto Tirelli and colleagues from the Center Riferimento Oncologico, Italy, and the Albert Einstein Comprehensive Cancer Center, New York. "The rationale for adding rituximab include its activity in refractory lymphoma, its non-overlapping toxicity and differing mechanism of action."

Tirelli et...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (2000-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry